Koers Charles River Laboratories International, Inc. Berne S.E.
Aandelen
RV6
US1598641074
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- CHF | -.--% |
|
-.--% | -.--% |
17/06 | Charles River Laboratories, Captain T Cell sluiten productieovereenkomst | MT |
13/06 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : Een koopadvies van Baird | ZM |
Omzet 2024 * | 4,22 mld. 3,75 mld. 3,94 mld. | Omzet 2025 * | 4,54 mld. 4,03 mld. 4,23 mld. | Marktkapitalisatie | 10,74 mld. 9,53 mld. 10,02 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 410 mln. 364 mln. 382 mln. | Nettowinst (verlies) 2025 * | 512 mln. 455 mln. 478 mln. | EV/omzet 2024 * | 3,01 x |
Nettoschuld 2024 * | 1,96 mld. 1,74 mld. 1,83 mld. | Nettoschuld 2025 * | 1,45 mld. 1,29 mld. 1,35 mld. | EV/omzet 2025 * | 2,69 x |
K/w-verhouding 2024 * |
26,2
x | K/w-verhouding 2025 * |
21,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,93% |
Recentste transcriptie over Charles River Laboratories International, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 01-01-76 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 25-04-22 |
Birgit Girshick
COO | Chief Operating Officer | 54 | 01-04-89 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 01-01-03 |
Virginia Wilson
BRD | Director/Board Member | 68 | 01-10-19 |
Robert Bertolini
BRD | Director/Board Member | 61 | 25-01-11 |
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,66% | 52,85 mld. | |
+35,57% | 38,24 mld. | |
-7,81% | 38,87 mld. | |
-10,77% | 26,79 mld. | |
+11,77% | 26,16 mld. | |
-17,82% | 19,9 mld. | |
+35,09% | 13,18 mld. | |
+29,17% | 12,24 mld. | |
-3,05% | 11,79 mld. |